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doi:10.1016/j.jmii.2011.01.022Background: Taipei Veterans General Hospital, one of the medical centers in Taiwan, has
provided highly active antiretroviral therapy (HAART) to human immunodeficiency virus/AIDS
patients for more than 10 years. Five years ago, we began a prospective follow-up of our
patients’ clinical manifestations and responses to HAART by collecting their clinical data.
In this study, we analyzed the morbidity, mortality, and responses to HAART of treatment-
naive AIDS patients. The purpose was to provide local data that may be valuable in Taiwan.
Methods: Study cases were enrolled from January 1, 2004, to February 28, 2009, with inclu-
sion criteria of newly diagnosed AIDS during hospitalization and being naive to HAART. Anti-
retroviral therapy was initiated. To evaluate the clinical responses to HAART, we excluded
patients who were pregnant, died within 1 month after confirmation of an AIDS diagnosis,
failed to initiate HAART, or were lost to follow-up for more than 6 months. Plasma viral loads
and CD4þ counts were quantified by reverse-transcriptase polymerase chain reaction and
flow cytometry, respectively. Statistical analysis was performed using SPSS statistical
software.
Results: A total of 49 patients were enrolled and 45 patients fulfilled the inclusion criteria
for evaluating the efficacy of HAART. At 3 months, 12 months, and 30 months after the initi-
ation of HAART, 64.4% (29 of 45), 88.2% (30 of 34), and 93.8% (15 of 16) had undetectable
plasma viral loads, respectively, and 37.8% (17 of 45), 73.5% (25 of 34), and 81.2% (13 ofnfectious Diseases, Department of Medicine, Taipei Veterans General Hospital, 201, Shih-Pai Road,
v.tw (S.-P. Yang).
an Society of Microbiology. Published by Elsevier Taiwan LLC. All rights reserved.
A 5-year retrospective study of AIDS in VGHTPE 19916) had CD4þ counts of more than 200 cells/mL, respectively. Median CD4þ counts increased
from baseline at Month 3 by 171 cells/mL and at Month 30 by 375 cells/mL. The overall
mortality was 22.4% (11 of 49).
Conclusion: The virologic and immunologic responses after initiating HAART in this study
demonstrated our achievements in providing care and treatment for AIDS patients during this
5-year period, which provides a strong evidence of the efficacy of HAART.
Copyright ª 2011, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
Since 1996, the widespread use of highly active anti-
retroviral therapy (HAART)da combination of at least three
drugs that typically includes either a protease inhibitor (PI)
or a non-nucleoside-analog reverse-transcriptase inhibitor
and two nucleoside-analog reverse-transcriptase inhibitors
(NRTIs)dhas substantially improved the prognosis of human
immunodeficiency virus (HIV)-infected patients.1e3 There
are several predictors of mortality for patients on anti-
retroviral therapy: viral load, CD4þ count, total lympho-
cytes, body mass index, and adherence. Randomized
clinical trials have provided strong evidence that HAART is
beneficial for patients with CD4þ count less than 200 cells/
mL4,5 and is also recommended for those with CD4þ counts
of 200e350 cells/mL.6 However, the optimum time to start
antiretroviral therapy among symptom-free patients with
CD4þ counts above this threshold and low or intermediate
viral loads is a matter of debate.7,8
According to the report of the Department of Health,
ROC (Taiwan), in April 2010, the seroprevalence rate of HIV
infection in Taiwan was 69.8 cases per 100,000 population,
with a total of 16,146 cases, which has been increasing in
recent years. The proportion of males to females was
nearly 11:1, and most patients were 15e39 years old,
a period of known sexual activity. The proportions of newly
reported HIV cases by mode of transmission in 2008 were as
follows: homosexuals and bisexuals, 42%; heterosexuals,
22.6%; and intravenous drug users, 33.7%;9 a clinical
spectrum similar to those in developed countries.10e12 All
HIV-infected patients were provided with free access to
inpatient or outpatient care, and antiretroviral therapy was
available at 42 designated hospitals around Taiwan.
The Taipei Veterans General Hospital (VGHTPE), one of
the medical centers in Taiwan, has provided care for HIV-
infected patients for two decades since the first native HIV-
infected patient was diagnosed at the VGHTPE in 1986.
However, until now, we have not presented our achieve-
ments in mortality reduction and improving the quality of
life of HIV-infected patients. In this prospective study, we
have characterized the clinical spectrum, morbidity,
mortality, and responses to HAART of AIDS patients in the
VGHTPE during the recent 5-year period.
Materials and methods
The study cases were enrolled from January 1, 2004, to
February 28, 2009. The inclusion criteria were patients
newly diagnosed with AIDS during hospitalization and
patients naive to HAART. Antiretroviral therapy wasprescribed during hospitalization or soon after discharge on
an outpatient basis. For follow-up to evaluate their clinical
spectrum, morbidity, mortality, and responses to HAART,
a standardized data collection form was used to record the
results of all histopathological and laboratory examina-
tions, complications associated with HIV infection, numbers
and durations of hospitalizations, regimens of prophylaxis,
and the antiretroviral therapy that was administered.
To evaluate the clinical responses to HAART of treat-
ment-naive patients, cases who were pregnant, died within
1 month after confirmation of AIDS diagnosis, failed to
initiate HAART, or were lost to follow-up for more than 6
months, were excluded. The HAART regimen administered
and a switch of the regimen in the presence of adverse
effects were according to the recommendations of the
Guidelines for the Use of Antiretroviral Agents in HIV-1-
Infected Adults and Adolescents, developed by the panel of
the Department of Health and Human Services, USA,6 and
the Guidelines for AIDS surveillance and treatment pub-
lished by the Center for Disease Control in Taiwan. Plasma
viral loads (PVLs) and CD4þ counts were checked before
HAART and at 1 month and 3 months after initiating ART. If
the virologic, immunologic, and clinical responses were
satisfactory, PVLs and CD4þ counts were followed up every
6 months thereafter. Outcome measures were the propor-
tions of patients with undetectable PVLs (<50 copies/mL)
and changes of CD4þ counts, calculated according to the
data checked at Months 3, 6, 12, 18, 24, 30, 36, 42, 48, 54,
and 60, after initiating HAART.
PVLs were quantified using reverse-transcription poly-
merase chain reaction with a Roche COBAS TaqMan 48 real-
time PCR analyzer (F. Hoffman-La Roche, Basel,
Switzerland). CD4þ counts were evaluated by flow cytom-
etry (FACS Calibur; Becton-Dickinson Diagnostic Instrument
System, Sparks, MD, USA). Hemograms and blood
biochemistries were also determined with the same blood
sampling scheduled for quantifying PVL and the CD4þ
count.
Categorical variables were compared using a Pearson
Chi-square test in terms of the virologic efficacy of HAART
between patients with baseline PVL of higher and lower
than 5 log10 copies/mL and baseline CD4
þ counts of higher
and lower than 50 cells/mL. Cox proportional-hazards
regression was used to estimate the influence of the
baseline PVL and CD4þ count on the immunologic response
of the CD4þ count after initiating HAART. We used
KaplaneMeier survival analysis to estimate any correlation
between patients’ mortality with baseline PVL and CD4þ
counts. Statistical analysis used SPSS statistical software
(Version 17.0; SPSS Inc. Chicago, IL, USA). A p value less
than 0.05 was considered to be statistically significant.
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From January 1, 2004, to February 28, 2009, 49 anti-
retroviral-naive patients were enrolled into this study.
Three patients (3 of 49) expired within 1 month after AIDS
diagnosis without receiving ART and one patient (1 of 49)
was lost to follow-up for more than 6 months. Only 45 (45 of
49) patients were eligible for evaluating the efficacy of
HAART. The baseline characteristics of these 49 newly
diagnosed AIDS patients are shown in Table 1.
Except for the lost baseline PVL data of one patient and
the baseline CD4þ count of one other patient, the averageTable 1 Clinical characteristics of 49 AIDS, antiretroviral-
naive Taiwan patients from January 1, 2004, to February 28,
2009













Baseline CD4þ lymphocyte (cells/mL)
Median 59.1
Range 1.5e185
Category of baseline CD4þ lymphocyte, n (%)
>200 cells/mL 0 (0)
100e199 cells/mL 12 (24.5)
50e99 cells/mL 11 (22.4)
<50 cells/mL 25 (51)
Lost data 1 (2)
Baseline PVL (log10 copies/mL), n (%)
Median 5.28
Range 1.29 to >7a
>5 log10 copies/mL 38 (77.6)
Lost data 1 (2)
Baseline CD4þ 50 cells/mL and PVL >5
log10 copies/mL, n (%)
19 (38.8)
Patients with AIDS-defining illness, n (%) 38 (77.6)






a One patient had PVL >7 log10 copies/mL, defined as 7 log10
copies/mL.
IDUZ intravenous drug user; MSMZmale who had sex with
male; PVLZ plasma viral load.baseline CD4þ count was 59.1 cells/mL (range: 1.5e185
cells/mL), and the average baseline PVL was 5.28 log10
copies/mL (1.29 to >7 log10 copies/mL). Among these
patients, 25 (25 of 49; 51%) had CD4þ counts of50 cells/mL;
38 (38 of 49; 77.6%) had PVLs＞5 log10 copies/mL; and 19 (19
of 49; 38.8%) had both of these.
There were four patients (4 of 49) with hepatitis B
infections, one (1 of 49) with hepatitis C infection, and one
(1 of 49) with both hepatitis B and C infections. Among
these patients, 38 (38 of 49) had active AIDS-defining
illnesses at enrollment, which included pneumocystis jir-
oveci pneumonia (PJP) (19), cytomegalovirus infection (6),
tuberculosis (4), cryptococcosis (3), non-Hodgkin’s
lymphoma (2), Kaposi sarcoma (2), nontuberculosis myco-
bacterium infection (3), and toxoplasmosis (2). Only one
patient each was noted for the following opportunistic
illnesses: amebiasis, esophageal candidiasis, herpes
simplex infection, herpes zoster, lymphoma of the central
nervous system, and salmonella septicemia.
Among the 45 patients who were eligible for the HAART
efficacy analysis, 32 had initial HAART of two NRTIs plus
efavirenz; 11 had two NRTIs plus a PI; and only two patients
who were enrolled in 2004 received initial HAART of rito-
navir, indinavir, and efavirenz. The initial NRTI regimens
included lamivudine plus abacavir for 16 patients, lam-
ivudine plus zidovudine for 20 patients, lamivudine plus
stavudine for five patients, lamivudine plus didanosine for
one patient, and abacavir plus stavudine for one patient.
The average observation duration for the responses to
HAART was 33.1 months (4e60 months). The virologic data
and immunologic responses are shown in Fig. 1. At 3
months, 12 months, and 30 months after the initiation of
HAART, 64.4% (29 of 45), 88.2% (30 of 34), and 93.8% (15 of
16) had undetectable PVLs, respectively, and 37.8% (17 of
45), 73.5% (25 of 34), and 81.2% (13 of 16), respectively, had
CD4þ counts of 200 cells/mL. The average CD4þ count
increased from baseline at Month 3 by 171 cells/mL and at
Month 30 by 375 cells/mL (Fig. 1). The average time was 7.6
months for the CD4þ count to reach the target (200 cells/
mL) and 6 months for the PVL to decline to the undetectable
range.
There were no significant differences for the virologic
responses between baseline PVL ofmore than and less than 5
log10 copies/mL and between CD4
þ counts of more than and
less than 50 cells/mL (pZ 0.982 and 0.887, respectively).
The immunologic response based on CD4þ counts was
significantly different between baseline CD4þ counts of
more than and less than 50 cells/mL (pZ 0.004, relative
riskZ 3.12, confidence intervalZ 1.44e6.76) (Table 2).
Only one virologic failure was noted after 24 months for
a patient treated with stavudine and lamivudine plus lopi-
navir/ritonavir; the regimen was shifted to lamivudine and
atazanavir plus didanosine, and the viral load subsequently
declined to the undetectable range. Two patients (2 of 34;
5.9%) had efavirenz-related hepatotoxicities, defined as
elevations of the aminotransferase levels to greater than five
times the upper normal limit. Allergic skin rashes attributed
todrugswerenoted in twopatients, onebecauseof efavirenz
and the other because of combivir. Other side effects
included zidovudine-related pancytopenia (1), stavudine-
related peripheral neuropathy (1), and indinavir-related
renal stones (1).
A 5-year retrospective study of AIDS in VGHTPE 201There were 11 fatalities in this study, and three of them
had expired within 1 month of the first hospitalization
before initiating ART. Five patients died from malignancies,
including visceral Kaposi’s sarcoma (3), brain lymphoma
(1), and hepatitis B virus (HBV)-related hepatocellular
carcinoma (1). The six other deaths were consequences of
opportunistic illnesses, including cryptococcal meningitis
(2), recurrent pneumonia (2), disseminated cytomegalo-
virus infection (1), and PJP infection (1). Comparing the
mortality rates among patients with baseline CD4þ counts
of higher and lower than 50 cells/mL, it was found that
there was no significant correlation between survival and
the baseline CD4þ count (pZ 0.105). However, the corre-
lation was significant between baseline PVL of higher and
lower than 5 log10 copies/mL and mortality (pZ 0.015)
(Table 2).
Discussion
HAART, which was introduced in Taiwan for AIDS patients in
1997, has demonstrated well its significant efficacy in
reducing plasma viral burdens and in controlling disease
progression in other studies conducted in Taiwan.11,13e16 In
this study, we found that our treatment-naive AIDS patients
mostly had advanced disease both clinically and immuno-
logically. Most of these patients were homosexual/bisexual
male patients, followed by heterosexuals, and intravenous
drug users were the minority, which was compatible with
the epidemiology of sexually transmitted routes accounting
for more than 90% of patients with high-risk behaviors
before 2003.10,12 The explanation for the aforementioned
findings is that most of the patients acquired HIV infection
before 2003 and developed to the AIDS stage after 2004.
Their advanced disease was evidence of their ignorance in
seeking medical consultation even with a high probability of
acquiring HIV infection because of high-risk behaviors. In
this era with evidence for the efficacy of HAART, moreMonths of follow up after HARRT (














Figure 1. Proportion of patients with CD4þ of 200 cells/mL and P
during follow-up after HAART treatment. HAARTZ highly active anefforts should be made for the early diagnoses of these
high-risk patients.
The regimens we chose appeared to be well tolerated in
view of the advanced disease, which necessitated the
concurrent use of multiple therapeutic or prophylactic
antimicrobial agents for opportunistic infections in most of
these patients, such as PJP and tuberculosis, for which
a mere seven patients (7 of 45; 15.6%) reported significant
adverse effects. Regarding the responses to HAART, the
virologic and immunologic response rates were satisfactory
before 36 months, but only a limited number of patients
(11) had been followed up for more than 36 months, which
resulted in decreased proportions of undetectable PVLs and
CD4þ counts of 200 cells/mL (Fig. 1).
The findings of our study indicated that the virologic
outcome was not related to the baseline CD4þ count or the
PVL, which was consistent with the observations by Phillips
et al.17 However, the immunologic outcomes were signifi-
cantly correlated with baseline CD4þ counts in this study,
which was comparable to a foreign study.18 Nevertheless,
the statistical analysis showed no differences in docu-
mented deaths between patients with baseline CD4þ counts
of more than and less than 50 cells/mL after initiating
HAART, which was inconsistent with the results in a foreign
study.18 A reasonable explanation is the short-term follow-
up and the limited numbers of cases in our study compared
with the populations in studies conducted in Western
countries. Also, the loss-to-follow-up rate was 2% (1 of 49)
for those who had received ART but were not seen in the
outpatient department for more than 1 year and had
incomplete data for evaluation.
The mortality rate was 22.4% (11 of 49). Among these
expired cases, seven patients died after receiving anti-
retroviral therapy, and four of these (4 of 7; 57.1%) had
expired within 6 months after initiating therapy. This was
assumed to be reasonable, as higher mortality rates and
disease progression were shown to be clustered amongNumber of follow-up patients) 
















Proportion of undetectable PVL
Mean CD4 count 
VL less than 50 copies/mL (undetectable), and the CD4þ count
tiretroviral therapy; PVLZ plasma viral loads.
Table 2 The correlation between baseline PVL/CD4þ count and virologic/immunologic response and mortality
n (%)a Virologic response Immunologic response Mortality
p p p
Baseline PVL 0.982 0.633 0.015b
5 log10 copies/mL 19/44 (43.2)
<5 log10 copies/mL 25/44 (58.6)
Baseline CD4þ count 0.887 0.004b 0.105
50 cells/mL 38/44 (86.4)
<50 cells/mL 6/44 (13.6)
a One patient lost baseline PVL data and the other lost baseline CD4þ count data.
b Statistically significant.
nZ number.
202 S.-F. Hsu et al.people with depleted baseline CD4þ counts.19 In our study,
it took an average of 6.8 months for the CD4þ count to
increase up to 200 cells/mL, and some of these patients
died before immunity was built up by HAART.
The major cause of mortality was AIDS-defining illness
(10 of 11; 90.9%), with only one death from HBV-related
hepatocellular carcinoma (HCC). According to the surveil-
lance done in Taiwan for 1994e2005,11 AIDS-defining illness
was the leading cause of mortality for HIV-infected patients
(59.7%). Another study conducted in Taiwan20 showed that
most AIDS-related conditions associated with death (cryp-
tococcosis and others) had decreased in frequency in
recent years after the introduction of HAART, and that
some AIDS-related conditions associated with death had
remained stable or even increased, such as candidiasis,
tuberculosis, and non-Hodgkin’s lymphoma.
On the whole, the response rate to HAART of these
treatment-naive patients was good, although antiretroviral
resistance tests were not done, as has been recommended
in the United States and Europe. Only one virologic failure
was noted after two NRTI plus a PI were administered for 24
months. After adjusting the HAART regimen, this patient
was followed up in our outpatient department with
continued undetectable PVL and a CD4þ count greater than
200. A surveillance study in Taiwan21 found that the
reported HAART resistance rate was 9.2%, which was higher
than that in 2008 (2.4%). One study22 suggested that
genotypic antiretroviral resistance testing (GART) should be
performed before initiating HAART when the resistance
rate was higher than 15%. Another study23 suggested that
all AIDS patients should receive GART before HAART in
those regions with a prevalence rate higher than 10%, if the
economic situation permitted. In Taiwan, GART is not rec-
ommended for treatment-naive patients, and our results
showed that the existing approach was feasible because of
the low resistance rate.
In this prospective study, we have described the clinical
spectrum, morbidity, mortality, and responses to HAART of
treatment-naive AIDS patients in the VGHTPE for the recent
5-year period. The HAART resistance rate in Taiwan was
lower than those in Western countries, and our study
patients responded to HAART well, although GART was not
performed initially. However, it has been noticed that the
resistance rate has been increasing in recent years,21 and
the comprehensive implementation of GART for treatment-
naive patients may be performed in the future.References
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